SecurityPTH / PowerShares Exchange-Trade Fund Trust (73935X351)
Institutional Owners8
Institutional Shares29,348
Institutional Value$ 2,190,000 USD

Institutional Stock Ownership and Shareholders

PTH / PowerShares Exchange-Trade Fund Trust Institutional Ownership

PowerShares Exchange-Trade Fund Trust (NASDAQ:PTH) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,348 shares. Largest shareholders include Commonwealth Equity Services, Inc, Niemann Capital Management Inc, National Asset Management, Inc., MetLife Securities, Inc, Ladenburg Thalmann Financial Services Inc, Citigroup Inc, Acorn Wealth Advisors, Llc, and Riggs Asset Managment Co. Inc..
PowerShares Exchange-Trade Fund Trust (NASDAQ:PTH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-13 13F-HR Advisor Group, Inc. 4,131 0 -100.00 315 0 -100.00
2018-08-13 13F-HR Certified Advisory Corp 24 0 -100.00 1 0 -100.00
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 83 0 -100.00 6 0 -100.00
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 3,492 0 -100.00 265 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 168,800 0 -100.00 12,857 0 -100.00
2018-07-19 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 3,814 0 -100.00 291 0 -100.00
2018-08-10 13F-HR ENVESTNET ASSET MANAGEMENT INC 16,367 0 -100.00 1,254 0 -100.00
2018-08-14 13F-HR AMERIPRISE FINANCIAL INC 6,290 0 -100.00 479 0 -100.00
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 7,020 0 -100.00 537 0 -100.00
2018-08-14 13F-HR Parallax Volatility Advisers, L.P. 1 0 -100.00 0 0
2018-08-10 13F-HR STEPHENS INC /AR/ 37,930 0 -100.00 2,889 0 -100.00
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 10,575 0 -100.00 805 0 -100.00
2018-08-07 13F-HR Highland Private Wealth Management 11,783 0 -100.00 897 0 -100.00
2018-08-10 13F-HR Acorn Wealth Advisors, Llc 238 238 0.00 19 21 10.53
2018-07-26 13F-HR SignalPoint Asset Management, LLC 10,566 0 -100.00 805 0 -100.00
2018-07-31 13F-HR CWM, LLC 91 0 -100.00 7 0 -100.00
2018-08-01 13F-HR G&s Capital Llc 41,052 0 -100.00 3,127 0 -100.00
2018-08-10 13F-HR CITIGROUP INC 1,474 0 -100.00 113 0 -100.00
2018-07-27 13F-HR Advisory Services Network, LLC 41 0 -100.00 3 0 -100.00
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 47,931 0 -100.00 3,651 0 -100.00
2018-08-14 13F-HR JP Morgan Chase & Co 1,414 0 -100.00 108 0 -100.00
2018-08-06 13F-HR Private Advisory Group LLC 11,783 0 -100.00 897 0 -100.00
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 834 0 -100.00 64 0 -100.00
2018-07-30 13F-HR Parallel Advisors, LLC 400 0 -100.00 30 0 -100.00
2018-08-14 13F-HR Centaurus Financial, Inc. 16,889 0 -100.00 1,286 0 -100.00
2018-07-30 13F-HR First Capital Advisors Group, LLC. 2,140 0 -100.00 163 0 -100.00
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 79,640 0 -100.00 6,066 0 -100.00
2018-08-15 13F-HR JANE STREET GROUP, LLC 35,187 0 -100.00 2,680 0 -100.00
2018-05-15 13F-HR National Asset Management, Inc. 6,767 7,092 4.80 488 541 10.86
2018-08-14 13F-HR ROYAL BANK OF CANADA 88,330 0 -100.00 6,729 0 -100.00
2018-07-27 13F-HR Riggs Asset Managment Co. Inc. 114 114 0.00 9 10 11.11
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 3,970 0 -100.00 304 0 -100.00
2018-08-01 13F-HR Financial Management Professionals, Inc. 30,555 0 -100.00 2,327 0 -100.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,945 1,945 0.00 148 148 0.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 71,484 0 -100.00 5,445 0 -100.00
2018-08-14 13F-HR HighTower Advisors, LLC 73,237 0 -100.00 5,582 0 -100.00
2018-08-10 13F-HR Calton & Associates, Inc. 8,529 0 -100.00 650 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 1,262 1,474 16.80 91 113 24.18
2018-08-03 13F-HR Seacrest Wealth Management, Llc 350 0 -100.00 27 0 -100.00
2018-08-06 13F-HR NIEMANN CAPITAL MANAGEMENT INC 0 7,249 0 635
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 30,092 0 -100.00 2,302 0 -100.00
2018-08-14 13F-HR STIFEL FINANCIAL CORP 19,491 0 -100.00 1,487 0 -100.00
2018-08-13 13F-HR Global Retirement Partners, Llc 270 0 -100.00 21 0 -100.00
2018-08-14 13F-HR UBS Group AG 138,547 0 -100.00 10,553 0 -100.00
2018-07-19 13F-HR EXANE DERIVATIVES 2,395 0 -100.00 180,753 0 -100.00
2018-07-23 13F-HR NewSquare Capital LLC 86 0 -100.00 7 0 -100.00
2018-07-25 13F-HR Transamerica Financial Advisors, Inc. 117 0 -100.00 9 0 -100.00
2017-01-13 13F-HR MetLife Securities, Inc 36,860 1,953 -94.70 531 94 -82.30
2018-08-10 13F-HR Cambridge Investment Research Advisors, Inc. 21,118 0 -100.00 1,609 0 -100.00
2018-08-07 13F-HR IFP Advisors, Inc 454 0 -100.00 35 0 -100.00
2018-08-13 13F-HR Westside Investment Management, Inc. 100 0 -100.00 7,260 0 -100.00
2018-07-19 13F-HR David R. Rahn & Associates Inc. 9,478 0 -100.00 722 0 -100.00
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 13,492 9,283 -31.20 584 628 7.53
2018-08-10 13F-HR Compagnie Odier SCA 650 0 -100.00 50 0 -100.00
2018-07-24 13F-HR Janney Montgomery Scott LLC 3,204 0 -100.00 244 0 -100.00
2018-08-14 13F-HR LPL Financial LLC 38,722 0 -100.00 2,949 0 -100.00
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 7,257 0 -100.00 553 0 -100.00
2018-08-13 13F-HR Stratos Wealth Partners, LTD. 1,071 0 -100.00 82 0 -100.00
2018-08-08 13F-HR CIBC World Markets Inc. 4,475 0 -100.00 341 0 -100.00
2018-08-15 13F-HR GLENMEDE TRUST CO NA 1,847 0 -100.00 133 0 -100.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

How To Avoid The Worst Sector ETFs Q1 2018

2018-03-28 seekingalpha
The following presents the least and most expensive sector ETFs as well as the worst overall sector ETFs per our Q1'18 sector ratings.

CUSIP: 73935X351